Xeltis has gained a European CE mark for aXess, with 12-month pivotal data of the vascular access graft for haemodialysis demonstrating strong and higher secondary patency versus conventional arteriovenous grafts (AVGs).
Xeltis’s aXess is a bioabsorbable graft for haemodialysis that is injected under the skin, promoting the growth of a patient’s own tissue to form a living, permanent blood vessel.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With the CE mark in hand, the Netherlands-based company intends to initiate commercial activities for its graft across Europe.
Xeltis’s regulatory approval was supported by its 120-patient pivotal trial. Of the real-world population, 69% of enrolled patients had previously used a central venous catheter (CVC) and had a failed fistula. The study’s findings demonstrated 79% secondary patency and a patency‑related reintervention rate of 1.3 per patient year, alongside what Xeltis called a ‘significant’ reduction in infection burden.
In comparison to alternative venous access options, the one-year pivotal data also revealed that patency‑related reinterventions were 60% lower than AVGs and 30% lower than arteriovenous fistulas (AVF), resulting in fewer access procedures for patients. At one year, the access‑related infection rate was 3%, versus 22% for CVCs and 9% for AVGs.
Xeltis CEO, Eliane Schutte, said: “The data demonstrate that aXess is safe and easy to implant, and by 12 months transforms into a tissue-like, pulsating conduit. With this level of clinical evidence, we can now move forward with the commercialisation of aXess and begin delivering it to patients in real-world clinical practice.”
Haemodialysis is a specific type of dialysis in which an external machine and a dialyser (artificial kidney) are used to filter blood. It is the most common treatment for kidney failure. The failure of vascular access is viewed as a common issue, one that can prove life-threatening for individuals who require haemodialysis on a regular basis. However, participants in the space highlight that securing dialysis clinic buy-in for technologies that aim to improve the treatment represents a considerable challenge, partly due to the lack of funding for kidney disease.
